Novel therapeutic agents in Waldenström's macroglobulinemia

Irene Ghobrial, Xavier Leleu, Abdel Kareem Azab, Judith Runnels, Xiaoying Jia, Hai Ngo, Molly Melhem, Feda Azab, Antonio Sacco, Phong Quang, Nicholas Burwick, Anne Sophie Moreau, Emanuel Husu, Mena Farag, Aldo Roccaro

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

Original languageEnglish (US)
Pages (from-to)84-86
Number of pages3
JournalClinical Lymphoma and Myeloma
Issue number1
StatePublished - 2009
Externally publishedYes

Bibliographical note

Funding Information:
Supported in part by the Kirsch Laboratory for WM, International Waldenstrom Macroglobulinemia Foundation, Leukemia and Lymphoma Society, and NIH R21 CA112904-01.


  • Akt
  • Bortezomib
  • Everolimus
  • Perifosine
  • Waldenström


Dive into the research topics of 'Novel therapeutic agents in Waldenström's macroglobulinemia'. Together they form a unique fingerprint.

Cite this